Eli Lilly Deal History & Licensing Activity
Eli Lilly is a large pharma headquartered in US. Over the past three years, Eli Lilly has been involved in 53 licensing and acquisition transactions, with a primary focus on Small Molecules (20 deals). The company currently has 50 active clinical trials, primarily in Metabolic.
Deals (12mo)
36
Active Trials
50
Top Modality
Small Molecules
Focus Area
Metabolic
Eli Lilly Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Eli Lilly in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Multi-target research collaboration (up to 5 targets) | Eli Lilly and Company | Other | Discovery | collaboration | Sep 24, 2026 |
| taRNA vaccine candidates for infectious diseases | Amplitude Therapeutics | mRNA | Discovery | collaboration | Sep 23, 2026 |
| MER769 | Lilly | Small Molecules | Preclinical | acquisition | Aug 31, 2026 |
| Ion channel antibody program | OmniAb | Antibodies | Discovery | license | Aug 17, 2026 |
| narmafotinib | Eli Lilly & Company | Small Molecules | Phase 1 | collaboration | Aug 4, 2026 |
| Undisclosed | AtaiBeckley | Other | Phase 1 | acquisition | Jul 16, 2026 |
| multitarget oncology programs | Abbisko Therapeutics | Small Molecules | Unknown | collaboration | Jun 24, 2026 |
| Capsid delivery, zinc finger, and MINT platforms; ST-506 prion-disease program | Eli Lilly and Company | Gene Therapy | Preclinical | acquisition | Jun 23, 2026 |
| BrainTransporter technology | BioArctic | Other | Discovery | collaboration | Jun 22, 2026 |
| Undisclosed | 4E Therapeutics | Small Molecules | Unknown | acquisition | Jun 16, 2026 |
Showing 10 of 20 recent transactions. Upgrade to Pro for full deal history with financials.
Eli Lilly Pipeline Focus
Therapeutic areas and modalities where Eli Lilly is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Eli Lilly Strategic Signals
Key indicators of Eli Lilly's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Eli Lilly Clinical Pipeline
Eli Lilly has 50 active clinical trials across 5 development phases.
6
Unknown
2
Phase 4
9
Phase 1
12
Phase 2
21
Phase 3
See How Your Asset Matches Eli Lilly's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Metabolic assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Eli Lilly Licensing & Deal Activity
Eli Lilly is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 53 deals over the past three years, Eli Lilly ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Eli Lilly include Metabolic (15 deals and trials), Oncology (14 deals and trials), Other (13 deals and trials), and Neurology (13 deals and trials). In terms of modality, Eli Lilly has shown particular interest in small molecules, other, gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Eli Lilly and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Eli Lilly's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.